Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

INTIRE TOX SCREEN

NPI: 1376950667 · GRAND PRAIRIE, TX 75050 · Clinical Medical Laboratory · NPI assigned 07/18/2014

$4K
Total Medicaid Paid
1,050
Total Claims
948
Beneficiaries
16
Codes Billed
2018-01
First Month
2019-12
Last Month

Provider Details

Authorized OfficialDELBOSQUE, MIGUEL (OWNER)
NPI Enumeration Date07/18/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 496 $4K
2019 554 $120.68

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 434 430 $2K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 286 286 $2K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 75 72 $0.00
81240 19 12 $0.00
81230 19 12 $0.00
81231 19 12 $0.00
81226 19 12 $0.00
81225 19 12 $0.00
81227 19 12 $0.00
81241 19 12 $0.00
81355 19 12 $0.00
81335 19 12 $0.00
81381 19 12 $0.00
81291 19 12 $0.00
81401 27 16 $0.00
81328 19 12 $0.00